Substituted 4-amino-benzylpiperidine compounds

Details Substituted 4-amino-benzylpiperidine compounds Substituted 4-amino-benzylpiperidine compounds

2008-03-06

2011-12-20

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S191000

Reexamination Certificate

active

08080565

ABSTRACT:
This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds.

REFERENCES:
patent: 3192206 (1965-06-01), Lunsford et al.
patent: 3192210 (1965-06-01), Lunsford et al.
patent: 3192221 (1965-06-01), Lunsford et al.
patent: 3984557 (1976-10-01), Welstead, Jr.
patent: 4002766 (1977-01-01), Welstead, Jr.
patent: 4594343 (1986-06-01), Shanklin, Jr. et al.
patent: 4810713 (1989-03-01), Yanni et al.
patent: 4950674 (1990-08-01), Yanni et al.
patent: 5026858 (1991-06-01), Vega-Noverola et al.
patent: 5028616 (1991-07-01), Desai et al.
patent: 5070087 (1991-12-01), Teng et al.
patent: 5096890 (1992-03-01), Cross et al.
patent: 5233053 (1993-08-01), Cross et al.
patent: 5281601 (1994-01-01), Cross et al.
patent: 5340831 (1994-08-01), Cross et al.
patent: 5344835 (1994-09-01), Alker et al.
patent: 5486527 (1996-01-01), Alker et al.
patent: 5607950 (1997-03-01), Alker et al.
patent: 5750540 (1998-05-01), Tsuchiya et al.
patent: 5932594 (1999-08-01), Cross et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6319920 (2001-11-01), Caroon et al.
patent: 6635764 (2003-10-01), Mammen et al.
patent: 6693202 (2004-02-01), Aggen et al.
patent: 7238709 (2007-07-01), Mammen et al.
patent: 7285564 (2007-10-01), Mammen et al.
patent: 7368463 (2008-05-01), Mammen et al.
patent: 2003/0055080 (2003-03-01), Forner et al.
patent: 2004/0054187 (2004-03-01), Mammen et al.
patent: 2004/0110229 (2004-06-01), Aggen et al.
patent: 2004/0116706 (2004-06-01), Mammen et al.
patent: 628 885 (1982-03-01), None
patent: 0 178 946 (1986-04-01), None
patent: 0 178 947 (1986-04-01), None
patent: 0 235 463 (1987-09-01), None
patent: 0 388 054 (1990-09-01), None
patent: 0 823 423 (1998-02-01), None
patent: 0 863 141 (1998-09-01), None
patent: 0 930 298 (1999-07-01), None
patent: 0 999 205 (2000-05-01), None
patent: 1 020 449 (2000-07-01), None
patent: 1 507 462 (1978-04-01), None
patent: 1 575 310 (1980-09-01), None
patent: 1 593 851 (1981-07-01), None
patent: WO 91/09013 (1991-06-01), None
patent: WO 99/43657 (1999-09-01), None
patent: WO 99/64043 (1999-12-01), None
patent: WO 01/04118 (2001-01-01), None
patent: WO 02/051841 (2002-07-01), None
patent: WO 02/053564 (2002-07-01), None
patent: WO 03/048124 (2003-06-01), None
patent: WO 2004/041806 (2004-05-01), None
Seddon “Pseudopolymorph . . . ” Crystal Gro. & des. p. 1087 (two pages from internet) (2004).
Braga et al. “Making crystals . . . ” J. Roy. Chem Soc. Chem. Commun. p. 3635-3645 (2005)Jord.
Jordan “Tamoxefin . . . ” Nature Rev. v.2, p. 205-213 (2003).
Vippagunta et al. “Crystalline solids . . . ” Adv. Drug. Del. Rev. v.48, p. 3-26 (2001).
Doods et al. “Therapeutic potential of . . . ” CA 118:139075 (1993).
Baker et al. “Central muscarinic . . . ” Ann. Rep. Med. Chem. v.24, p. 31-40 (1999).
Parkeman et al. “Subtype of muscarinic . . . ” Am. J. Phy. Gastrointest. Liver Physiol. vo. 276, p. G1243-G1250 (1999) with 5 pages attachment of chemical structure.
Broadley et al., “Muscarinic Receptor Agonists and Antagonists”, Molecules 2001, 6, pp. 142-193 (2001).
Eglen et al., “Muscarinic Receptor Subtypes: Pharmacology and Therapeutic Potential”, DN&P, 10(8), pp. 462-469 (1997).
Eglen et al., “Selective modulation of muscarinic receptor subtypes: therapeutic potential”, Emerging Drugs:The Prospect for Improved Medicines/Annual Executive Briefing 1998; pp. 67-79 (1998).
Graul et al., “Darifenacin”, Drugs of the Future 1996, 21 (11); pp. 1105-1108 (1996).
Moragues et al., “Dopaminergic Activity in a Series of N-Substituted 2-Aminopyrimidines”, II Farmaco—Ed. Sc.—vol. 35—Fasc. 11; pp. 951-964 (1980).
Shum et al., “The Design and Synthesis of Purine Inhibitors of CDK2.III”, Nucleosides, Nucleotides & Nucleic Acids, 20(4-7), pp. 1067-1078 (2001).
Taniguchi et al., “Agents for the Treatment of Overactive Detrusor. VI.1a)Synthesis and Pharmacological Properties of Acetamide Derivatives Bearing Cyclic Amines inN-Substituents”, Chem. Pharm. Bull., 42(1) pp. 74-84 (1994).
Zlotos et al., “Muscarinic receptor agonists and antagonists”, Exp. Opin. On Ther. Patents, 9(8), pp. 1029-1053 (1999).
Berge et al. “Pharmaceutical salts”, J. Pharm. Sciences, vol. 66, pp. 1-2 (1977).
CA 60:74793 (1964).
Pratesi et al. “Affinity and Intrinsic . . . ” CA 70:37081 (1969).
Laeckmann et al. “Synthesis and biological evaluation of aroylguanidines related to amiloride as inhibitors of the human platelet Na+/H+ exchanger”, Bioorg. Med. Chem., vol. 10, pp. 1793-1804 (2002).
Wermuth “The practice of medicinal chemistry”, pp. 203-213 (1996).

Affiliated with

Also associated with

Rating

Substituted 4-amino-benzylpiperidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted 4-amino-benzylpiperidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4-amino-benzylpiperidine compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4271291